Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 6, 2017
Principal Event: Entry into a new six-year Sourcing and Supply Agreement with Amgen USA Inc. for erythropoiesis stimulating agents (Epogen and Aranesp), replacing prior agreements.
Key Financial Metrics
This filing is a current report regarding a material agreement and does not contain audited financial statements, revenue, profit, cash flow, or debt figures for a specific reporting period. However, it includes forward-looking operating income guidance for 2017:
- Kidney Care Segment 2017 Operating Income: Expected between $1.525 billion and $1.625 billion.
- DaVita Medical Group (DMG) Segment 2017 Operating Income: Expected to be roughly flat compared to 2016 adjusted operating income.
Note: Complete 2017 operating income guidance was scheduled to be provided in the fourth quarter 2016 earnings announcement.
Material Changes Versus Prior Period
- Agreement Termination: The Company terminated the previous Sourcing and Supply Agreement (effective 2012, expiring 2018) and the Dialysis Organization Agreement (effective 2015) on January 6, 2017.
- New Commitment: The new agreement requires DaVita to purchase a minimum of 90% of its requirements for Epogen and Aranesp from Amgen annually through December 31, 2022.
- Pricing Structure: The new agreement provides for discount pricing and rebates, some of which are subject to conditions and data submission by DaVita.
Guidance, Outlook, and Risks
Management Commentary: Management expects the new agreement to impact 2017 operating income as detailed in the guidance above. The agreement allows for termination in the event of breaches and modification in the event of changes in law or regulation.
Risks and Contingencies: The filing includes a comprehensive cautionary statement regarding forward-looking statements. Key risks identified include:
- Downward pressure on payment rates from commercial payors and potential reductions in government reimbursement rates (Medicare ESRD).
- Impact of healthcare exchanges and regulatory changes on patient enrollment and reimbursement.
- Legal compliance risks, including adherence to the Corporate Integrity Agreement (CIA) and ongoing government investigations.
- Competition from other dialysis providers and emerging care models (e.g., ACOs, IPAs).
- Risks specific to the DaVita Medical Group, including network disruptions and quality rating reductions.
Investor Verification Checklist
- Verify the final 2017 operating income guidance once released in the Q4 2016 earnings announcement.
- Review the full text of the Sourcing and Supply Agreement (expected as an exhibit to a future periodic report) to understand specific rebate conditions.
- Monitor updates on the Company's Corporate Integrity Agreement (CIA) and any related government investigations.
- Track changes in Medicare Advantage benchmark structures and commercial payer reimbursement rates.
- Assess the integration and performance of the DaVita Medical Group segment relative to the "flat" operating income expectation.